Plain-English translation of NCT05444712 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether patients with peripheral T-cell lymphoma—a rare type of blood cancer affecting immune cells—benefit from receiving a stem cell transplant after completing chemotherapy. You would receive chemotherapy first; if your cancer responds well, you may then receive high-dose chemotherapy followed by your own stem cells (collected beforehand) being put back into your body to help rebuild your immune system. Researchers want to know if this extra step helps people live longer without their cancer returning.
Peripheral T-cell lymphoma is very aggressive and has a poor prognosis—most patients don't survive 10 years. Doctors aren't sure whether the additional stem cell transplant actually helps patients after they've already responded to chemotherapy, so this trial is designed to find the best approach.
You likely qualify if…
You likely don't qualify if…
You would receive chemotherapy (one of three standard regimens) given every 3 weeks for 6 cycles at your treatment center. Your doctor will then check if your cancer has responded well. If it has, you'll receive high-dose chemotherapy over 2–3 months followed by an infusion of your own stem cells that were collected earlier. Throughout the trial, you'll have regular blood tests, scans, and clinic visits to monitor your health and how well the treatment is working. The entire process from starting chemotherapy through stem cell recovery typically takes several months.
AI-generated summary from trial data · Jun 15, 2026 · Not medical advice
France